Hypothesis

Quercetin phytosome achieves high systemic exposure but fails to reach therapeutically relevant concentrations in the brain; nevertheless, it attenuates age‑related neuronal senescence by suppressing peripheral senescence‑associated secretory phenotype (SASP) factors that drive microglial activation and secondary neuronal stress.

Mechanistic Rationale

• Quercetin phytosome yields ~18‑20‑fold higher plasma AUC than unformulated quercetin at equal doses [1,2], yet free quercetin only attains picomolar‑nanomolar levels in rodent brain [4].
• Senolytic activity in vitro requires micromolar quercetin (~10‑50 µM) [5]; plasma concentrations from phytosome (~low‑µM) are still an order of magnitude below this threshold, making direct neuronal senolysis unlikely.
• Peripheral senescent cells (e.g., in adipose tissue, vasculature) release IL‑6, TNF‑α, and MMPs that can cross a leaky blood‑brain barrier or signal via vagal afferents, priming microglia to a pro‑inflammatory state [3].
• Quercetin inhibits NF‑κB signaling and reduces SASP secretion in peripheral senescent cells [5], thereby lowering the cytokine load that sustains microglial activation.
• Microglial priming influences synaptic stripping and the elimination of metabolically inefficient neurons, a process that resembles developmental pruning but is amplified in aging [5].

Testable Predictions

1. Phytosome treatment will reduce circulating SASP factors (IL‑6, TNF‑α, MCP‑1) in aged mice without significantly increasing brain quercetin levels.
2. Despite low brain quercetin, treated animals will show decreased microglial activation markers (Iba1, CD68) and lower neuronal senescence markers (p16^INK4a^, γH2AX) in cortical and hippocampal tissue.
3. Cognitive performance will improve in parallel with peripheral SASP reduction, and this improvement will be abrogated by peripheral administration of recombinant IL‑6 or by microglial depletion (e.g., PLX5622 diet).
4. Co‑administration of a BBB‑penetrant quercetin nanocarrier will not produce additive cognitive benefits over phytosome alone if the primary mechanism is peripheral.

Experimental Design (falsifiable)

• Groups (n = 12 per group, 24‑month‑old C57BL/6 mice): vehicle, quercetin phytosome (50 mg/kg PO daily), free quercetin (50 mg/kg), phytosome + peripheral IL‑6 rescue, phytosome + microglial inhibitor.
• Measurements (after 8 weeks): plasma quercetin (LC‑MS), brain quercetin (homogenate LC‑MS), plasma SASP cytokine panel, brain immunohistochemistry for Iba1, p16, neuronal NeuN loss, and behavioral battery (Morris water maze, novel object recognition).
• Falsification criteria: If phytosome does not lower peripheral SASP yet still improves cognition, or if brain quercetin reaches micromolar levels concurrent with cognitive gain, the hypothesis is refuted.

Significance

This reframes the quercetin‑brain aging debate: systemic senolytics may preserve neuronal function indirectly by quieting the inflammatory milieu that drives microglia‑mediated neuronal eviction, opening combinatorial strategies that pair peripheral senolytics with targeted BBB delivery for synergistic impact.